Literature DB >> 6408122

Interaction of phosphatidylserine-phosphatidylcholine liposomes with sickle erythrocytes. Evidence for altered membrane surface properties.

R S Schwartz, N Düzgünes, D T Chiu, B Lubin.   

Abstract

The sickle erythrocyte (RBC) is a pathologic RBC that contains multiple membrane abnormalities. Some of these abnormalities have been implicated in the pathophysiology of vasoocclusive crises characteristic of sickle cell disease; others have yet to be defined in terms of their clinical significance. Recent information has shown that sickle RBC adhere abnormally to cultured endothelial cells yet little is known about the ways in which sickle cells interact with model membranes of defined size and lipid composition. We investigated this phenomenon by interacting sickle RBC with artificial lipid vesicles (liposomes) containing acidic phospholipids. Our results demonstrate that sickle disease (hemoglobin SS) RBC bind more of these liposomes than do normal or sickle trait (hemoglobin AS) RBC and that these differences are accentuated by hypoxia-induced sickling. Binding of liposome phospholipid to sickled RBC was not attributable to phospholipid exchange between liposomes and RBC and was consistent with a mechanism involving both membrane fusion and a stable reversible adhesion of liposomes to the RBC membrane.Investigations into the mechanism(s) underlying increased liposome binding to sickled RBC suggested that the known reversible translocation of aminophospholipids, phosphatidylserine (PS) and phosphatidyl-ethanolamine (PE), from the inner to the outer leaflet of the reversibly sickled RBC (RSC) plasma membrane during sickling may be a component of increased liposome binding to RSC. This idea was supported from results of experiments in which normal RBC were treated with diamide resulting in the expression of outer leaflet PE and PS and a stimulation of liposome binding to these cells. However, sickle RBC separated according to cell density on stractan gradients showed that irreversibly sickled RBC (ISC) were less capable of liposome binding than were discoid RSC. Since ISC are known to contain elevated levels of outer leaflet aminophospholipids, such a result suggests that other changes in the plasma membrane of sickle cells, in addition to phospholipid reorganization, are probably involved in enhanced liposome binding to these cells. In other experiments, we showed that liposomes containing l-phenylalanine were capable of delivering this antisickling agent into intact sickle RBC as demonstrated by the partial inhibition of hypoxia-induced sickling in vitro. Our results suggest that liposomes can be used as sensitive probes for investigating changes in RBC membrane properties, especially those that affect intermembrane interactions, and that liposomal transport systems may have significant implications in the therapy of sickle cell disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6408122      PMCID: PMC370363          DOI: 10.1172/jci110913

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  Studies on membrane fusion. III. The role of calcium-induced phase changes.

Authors:  D Papahadjopoulos; W J Vail; C Newton; S Nir; K Jacobson; G Poste; R Lazo
Journal:  Biochim Biophys Acta       Date:  1977-03-17

2.  Clustering and endocytosis of membrane receptors can be induced in mature erythrocytes of neonatal but not adult humans.

Authors:  R Schekman; S J Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1976-11       Impact factor: 11.205

Review 3.  Hemolysis in sickle cell disease.

Authors:  T A Bensinger; P N Gillette
Journal:  Arch Intern Med       Date:  1974-04

4.  Elevated erythrocyte calcium in sickle cell disease.

Authors:  J W Eaton; T D Skelton; H S Swofford; C E Kolpin; H S Jacob
Journal:  Nature       Date:  1973-11-09       Impact factor: 49.962

5.  Phospholipid model membranes. I. Structural characteristics of hydrated liquid crystals.

Authors:  D Papahadjopoulos; N Miller
Journal:  Biochim Biophys Acta       Date:  1967-09-09

6.  Separation of erythrocytes according to age on a simplified density gradient.

Authors:  L M Corash; S Piomelli; H C Chen; C Seaman; E Gross
Journal:  J Lab Clin Med       Date:  1974-07

7.  Irreversible deformation of the spectrin-actin lattice in irreversibly sickled cells.

Authors:  S E Lux; K M John; M J Karnovsky
Journal:  J Clin Invest       Date:  1976-10       Impact factor: 14.808

8.  Abnormal rheology of oxygenated blood in sickle cell anemia.

Authors:  S Chien; S Usami; J F Bertles
Journal:  J Clin Invest       Date:  1970-04       Impact factor: 14.808

9.  Exchange of various phospholipids and of cholesterol between liposomes in the presence of highly purified phospholipid exchange protein.

Authors:  C Ehnholm; D B Zilversmit
Journal:  J Biol Chem       Date:  1973-03-10       Impact factor: 5.157

10.  Denatured hemoglobin in sickle erythrocytes.

Authors:  T Asakura; K Minakata; K Adachi; M O Russell; E Schwartz
Journal:  J Clin Invest       Date:  1977-04       Impact factor: 14.808

View more
  4 in total

1.  Concurrent sickle cell anemia and alpha-thalassemia. Effect on pathological properties of sickle erythrocytes.

Authors:  S H Embury; M R Clark; G Monroy; N Mohandas
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

2.  Increased adherence of sickled and phosphatidylserine-enriched human erythrocytes to cultured human peripheral blood monocytes.

Authors:  R S Schwartz; Y Tanaka; I J Fidler; D T Chiu; B Lubin; A J Schroit
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

3.  Stability of echogenic liposomes as a blood pool ultrasound contrast agent in a physiologic flow phantom.

Authors:  Kirthi Radhakrishnan; Kevin J Haworth; Shao-Ling Huang; Melvin E Klegerman; David D McPherson; Christy K Holland
Journal:  Ultrasound Med Biol       Date:  2012-08-25       Impact factor: 2.998

4.  Abnormality of phospholipid transverse diffusion in sickle erythrocytes.

Authors:  A Zachowski; C T Craescu; F Galacteros; P F Devaux
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.